Skip to Main Content

Impact of HIV Infection on Immunologic, Transcriptomic, and Metabolomic Signatures

Conditions

Addictive Behaviors | HIV/AIDS | Infectious Diseases

What is the purpose of this trial?

The purpose of this study is to understand changes in how your blood cells, genes, metabolism, and immune system work after you begin medication assisted therapy (MAT) (e.g. buprenorphine/naloxone, buprenorphine, methadone or extended-release naltrexone), for treatment of an opioid use disorder. The researchers will follow all participants and schedule regular interviews and blood draws to gather information. This will enable them to look at the presence of specific factors associated with treatment for opioid use disorder in those living with HIV infection and those without HIV infection. The study will last for 6 months.

  • Trial with
    National Institute on Drug Abuse (NIDA)
  • Start Date
    03/31/2017
  • End Date
    08/31/2021
Trial Image

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    02/05/2019
  • Study HIC
    #1608018239